Psion
SELLWeak North American demand is damaging mobile computing counter Psion, the provider of solutions including software, rugged hardware and secure wireless networks.
In a December 2007 trading update that wiped 15% from the share price, Psion said sales from Europe, the Middle East and Africa were growing satisfactorily and sales from Asia strongly, which is encouraging as two thirds of overall sales emanate from these combined regions. However, demand in the Americas continues to slow, in particular from the transport and logistics sectors. And although several delayed large North American contracts have subsequently been signed in the second half, buying decisions are being delayed as the credit crunch-inspired economic crisis across the Pond grows.
As a result, Psion’s annual US dollar sales will be 8% south of last year’s $135m (£65.5m). On translation, investors are looking at a 15% regional revenue reversal, implying very modest sterling sales growth on last year’s £191m. Subsequently, analysts have cut 2007 sales forecasts from £201m to £193m, pegging back pre-tax estimates by 30% to £10.3m and forecast earnings from 6.8p to 5p.
Despite weak US trading, costs are said to be under control, new products, such as the Ikon rugged PDA, have been well received and recent acquisitions give cause for encouragement.
Nevertheless, although Psion trades on a modest price-to-sales ratio of 0.75 times, downgraded earnings forecasts place the shares on a pricey forward multiple of 21 times even after the share price correction. Bearing in mind the old adage about buses arriving in threes, the risk profile has increased. Sell.
Save 50% off your first year’s subscription to Growth Company Investor magazine, and gain immediate access to all the recommendations online. Click here.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £146.3m
PE Forecast: 21
Share price: 104.75p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
